Impact of long-term use of enapril, losartan and their combinations on life quality in patients with congestive heart failure

Terapevticheskii Arkhiv

Volumn 74, Issue 1, 2002, Pages 52-55

  Vizir, V A ^a   Berezin, A Ye ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; MIDDLE AGED; QUALITY OF LIFE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN;

EID: 0036371504     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Thompson D. R., Meadows K. A., Lewin R. J. P. Measuring quality of life in patients with coronary heart disease. Eur. Heart J. 1998; 19: 693-695.
2. Guyatt G. H., Feeny D. H., Patrick D. Measuring health-related quality of life Am. Intern. Med. 1993; 118:622-629.
3. Valentini L., Lim L., Heller R. F., Knapp J. An improved questionnaire for assessing quality of life after acute muocardial infarction. Qual. Life Res. 1996; 5: 151-161
4. Mayon R., Bryant B. Quality of life in cardiovascular disease. Br. Heart J. 1993; 69: 460-466.
5. McGee H. M. Can the measurement of quality of life contribute to evaluation in cardiac rehabilitation services. J. Cardiovasc. Risk. 1996; 3: 148-153.
6. Cowburn P. J., Cleland J. G. F., Coats A. J. S., Komnjda M. Risk stratification in chronic heart failure. Eur. Heart J. 1998; 19: 696-710.
7. Pool-Wilson P. et al. (Eds.) Heart Failure. London: Churchill Livingstone; 1997: 900.
8. Nolan J., Batin P. D., Andrews R. et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdome Heart Failure Evaluation and Assessment of Risk Trial (UK - HEART). Circulation. 1998; 98: 1510-1516
9. The ATLAS - Assessment of Treatment Lisinopril and Survival CD: ATLAS, Astra Zeneca; 1999.
10. Pitt B., Poole- Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study-ELITE II.J. Cardiac. Failure 1999; 5(2): 146-154.
11. Van Veldhuisen D. J., Voors A. A. Blockade of the renin angiotensin system in heart failure: potential place of angiotensin II receptor blokers. Eur. Heart J. 2000; 21: 14-16.
12. Oparil S., Guthrie R., Lewin A et al An elective-titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. Clin. Ther. 1998; 20(3): 398-409.
13. McInnes G. Angiotensin II receptor antagonists. London; 1998.
14. Rector T. C., Kubo S. H., Cohn J. N. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure question naive Heart Failure 1987; 10: 198-209.
15. Ishiyama T., Marita Y., Toyama S. A clinical study of the effect of coenzyme Q on congestive heart failure Jap. Heart J. 1976; 17: 32-42.
16. Cowley A. J., Wiens B. L., Segal R. et al. Quality of life in elderly patients with symptomatic heart failure: losartan versus captopril. Eur. Heart J. 1998; 19: 134.